186 related articles for article (PubMed ID: 29190165)
21. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
[TBL] [Abstract][Full Text] [Related]
23. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study.
Galor A; Karp CL; Chhabra S; Barnes S; Alfonso EC
Br J Ophthalmol; 2010 May; 94(5):551-4. PubMed ID: 19493859
[TBL] [Abstract][Full Text] [Related]
24. Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study.
Parrozzani R; Frizziero L; Trainiti S; Testi I; Miglionico G; Pilotto E; Blandamura S; Fassina A; Midena E
Br J Ophthalmol; 2017 Aug; 101(8):1094-1099. PubMed ID: 27941046
[TBL] [Abstract][Full Text] [Related]
25. Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia.
Holcombe DJ; Lee GA
Am J Ophthalmol; 2006 Oct; 142(4):568-71. PubMed ID: 17011846
[TBL] [Abstract][Full Text] [Related]
26. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
Blasi MA; Maceroni M; Sammarco MG; Pagliara MM
Eur J Ophthalmol; 2018 Mar; 28(2):204-209. PubMed ID: 28967069
[TBL] [Abstract][Full Text] [Related]
27. Medical treatment for ocular surface squamous neoplasia.
Monroy D; Serrano A; Galor A; Karp CL
Eye (Lond); 2023 Apr; 37(5):885-893. PubMed ID: 36754986
[TBL] [Abstract][Full Text] [Related]
28. Chronic inflammation as a proposed risk factor for ocular surface squamous neoplasia.
De Arrigunaga S; Wall S; Theotoka D; Friehmann A; Camacho M; Dubovy S; Galor A; Karp CL
Ocul Surf; 2024 Jul; 33():1-10. PubMed ID: 38432640
[TBL] [Abstract][Full Text] [Related]
29. Interferon Alfa-2b for Pigmented Ocular Surface Squamous Neoplasia: A Report of 8 Lesions.
Kaliki S; Sharma A; Vempuluru VS
Cornea; 2021 Feb; 40(2):142-146. PubMed ID: 32355112
[TBL] [Abstract][Full Text] [Related]
30. Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature.
Kalamkar C; Radke N; Mukherjee A; Radke S
BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27166000
[TBL] [Abstract][Full Text] [Related]
31. Ocular surface squamous neoplasia (squamous cell carcinoma) of the socket: management of extensive tumors with interferon.
Shields CL; Kancherla S; Bianciotto CG; Lally SE; Shields JA
Ophthalmic Plast Reconstr Surg; 2011; 27(4):247-50. PubMed ID: 21242851
[TBL] [Abstract][Full Text] [Related]
32. Corneal squamous neoplasia: masquerades and management outcomes at a rural eyecare centre.
Agarwal A; Kaliki S; Murthy SI
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37130635
[TBL] [Abstract][Full Text] [Related]
33. Prevalence, treatment, and outcomes of coexistent ocular surface squamous neoplasia and pterygium.
Oellers P; Karp CL; Sheth A; Kao AA; Abdelaziz A; Matthews JL; Dubovy SR; Galor A
Ophthalmology; 2013 Mar; 120(3):445-450. PubMed ID: 23107578
[TBL] [Abstract][Full Text] [Related]
34. Observational study of ocular surface squamous neoplasia: Risk factors, diagnosis, management and outcomes at a tertiary eye hospital in South Africa.
Hӧllhumer R; Williams S; Michelow P
PLoS One; 2020; 15(8):e0237453. PubMed ID: 32780766
[TBL] [Abstract][Full Text] [Related]
35. Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Wylegala A; Sripawadkul W; Zein M; Alvarez OP; Al Bayyat G; Galor A; Karp CL
Ocul Surf; 2023 Jan; 27():67-74. PubMed ID: 36476665
[TBL] [Abstract][Full Text] [Related]
36. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
Boehm MD; Huang AJ
Ophthalmology; 2004 Sep; 111(9):1755-61. PubMed ID: 15350333
[TBL] [Abstract][Full Text] [Related]
37. Ocular surface squamous neoplasia: angiographic characteristics and response to subconjunctival/perilesional 5-fluorouracil injections.
Sun Y; Hua R
Drug Des Devel Ther; 2019; 13():1323-1334. PubMed ID: 31118569
[No Abstract] [Full Text] [Related]
38. Surgical versus Medical Treatment of Ocular Surface Squamous Neoplasia: A Cost Comparison.
Moon CS; Nanji AA; Galor A; McCollister KE; Karp CL
Ophthalmology; 2016 Mar; 123(3):497-504. PubMed ID: 26686965
[TBL] [Abstract][Full Text] [Related]
39. Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.
Kozma K; Dömötör ZR; Csutak A; Szabó L; Hegyi P; Erőss B; Helyes Z; Molnár Z; Dembrovszky F; Szalai E
Sci Rep; 2022 Aug; 12(1):14221. PubMed ID: 35987957
[TBL] [Abstract][Full Text] [Related]
40. Amniotic Membrane Grafting for Ocular Surface Inflammation Following Topical Interferon Alpha 2b Therapy.
Shah SG; Mishra DK; Shah GY
J Interferon Cytokine Res; 2022 Mar; 42(3):137-139. PubMed ID: 35298286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
